Schrödinger Q1 FY24 Investor Presentation

Schrödinger presented its Q1 FY24 results focusing on accelerating drug development timelines and reducing R&D costs through science-based software and consulting solutions. The presentation discusses the company's competitive advantages, recent Immunetrics acquisition integration, and market position in the pharmaceutical software sector.